News
Treating Fragile X syndrome with the diuretic bumetanide: a case report
We report that daily administration of the diuretic NKCC1 chloride co-transporter, bumetanide, reduces the severity of autism in a 10-year-old Fragile X boy using CARS, ADOS, ABC, RDEG and RRB before and after treatment. In keeping with extensive clinical use of this diuretic, the only side effect was a small hypokalaemia. A double-blind clinical trial is warranted to test the efficacy of bumetanide in FRX.
Eric Lemonnier 1 , Gaëlle Robin, Céline Degrez, Roman Tyzio, Marine Grandgeorge, Yehezkel Ben-Ari
Scientific papers
- Smaller brain volumes after birth by Cesarean Section 24 March 2021
- The GABA developmental sequence is altered in a mouse model of Rett Syndrome 26 June 2019
- No stop-growing signal around birth in a rodent model of autism 24 January 2019
- Immune activation during gestation leads to hippocampal neuronal alterations already at birth 4 November 2018
- A promising multicenter trial to alleviate autistic disorders 14 March 2017
- The diuretic Bumetanide and the birth hormone Oxytocin point to a common pathway in the early pathogenesis of Autism in rodents 26 February 2014
- Treating Fragile X syndrome with the diuretic bumetanide: a case report 10 June 2013
- A randomised controlled trial of bumetanide in the treatment of autism in children 11 December 2012
- The GABA excitatory/inhibitory shift in brain maturation and neurological disorders 18 October 2012